Myriad Genetics, Inc. MYGN

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
48/100
Developing

Ranked against 61 peers in Diagnostics & Research

About Myriad Genetics, Inc.

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with … Full MYGN analysis →

Key strengths

  • Elite Gross Margins Gross margin quality is top-tier vs peers (score 0.91). This signals strong consumable attach-rate economics.
  • Stable Gross Margin Profile Gross margin stability is strong (score 0.95). Low volatility confirms durable consumable pricing.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.22). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Below-Peer Operating Margin Operating margin level is below peers (score 0.27). SG&A leverage needs improvement to close the gap.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Strong
93
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Where MYGN ranks in Diagnostics & Research

Myriad Genetics, Inc. ranks #36 of 62 scored companies in Diagnostics & Research by moat score — the top 58%. The widest moat in the group is IDEXX Laboratories, Inc. (IDXX) at 78/100.

# Company Moat score Rating
32 NeoGenomics, Inc. NEO 50/100 Developing
33 Prenetics Global Limited PRE 50/100 Developing
34 Prenetics Global Limited PRENW 50/100 Developing
35 Twist Bioscience Corporation TWST 50/100 Developing
36 Myriad Genetics, Inc. MYGN 48/100 Developing
37 Star Equity Holdings, Inc. - Se STRRP 47/100 Developing
38 Star Equity Holdings, Inc. STRR 47/100 Developing
39 Neuronetics, Inc. STIM 45/100 Developing
40 Exagen Inc. XGN 44/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How MYGN scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 92 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 23 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 58 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 21 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 27 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 34 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding MYGN's moat

What is Myriad Genetics, Inc.'s moat score?

Myriad Genetics, Inc. (MYGN) scores 48 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #36 of 62 scored companies in Diagnostics & Research, the top 58%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Diagnostics & Research. Its strongest defense is Pricing Power & Consumable Moat (92/100) and its weakest is Commercial Execution (21/100).

How does Myriad Genetics, Inc. compare with other Diagnostics & Research companies?

Myriad Genetics, Inc. ranks #36 of 62 scored companies in Diagnostics & Research by moat score. The widest moat in Diagnostics & Research is IDEXX Laboratories, Inc. (IDXX) at 78/100. The companies ranked closest are Twist Bioscience Corporation (TWST) at 50 just above it and Star Equity Holdings, Inc. - Se (STRRP) at 47 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Diagnostics & Research. The defenses are then weighted to produce the overall score out of 100.

Why is Myriad Genetics, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Myriad Genetics, Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and MYGN scores: Pricing Power & Consumable Moat (92), R&D Pipeline & Capital Returns (23), FCF Quality & Cash Conversion (58), Commercial Execution (21), Capital Structure & Resilience (27), Growth Durability (34). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000